LISATA THERAPEUTICS INC. - COMMON STOCK

Lisata Therapeutics and WARPNINE Announce Encouraging Preliminary Results from the Phase 1b/2a iLSTA Trial Evaluating Certepetide in Locally Advanced Non-Resectable Pancreatic Ductal Adenocarcinoma

23 1 2025 07:00:00 提供 Nasdaq GlobeNewswire

Lisata Therapeutics Reports Encouraging Preliminary Cohort A Data from the AGITG-led Phase 2 ASCEND Trial Evaluating Certepetide with Standard-of-Care Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma

22 1 2025 07:00:00 提供 Nasdaq GlobeNewswire

Lisata Therapeutics to Present at the 2025 Sequire Investor Summit

15 1 2025 07:30:00 提供 Nasdaq GlobeNewswire

Lisata Therapeutics Announces Completion of Enrollment in the CENDIFOX Trial

10 12 2024 07:30:00 提供 Nasdaq GlobeNewswire

Lisata Therapeutics and Kuva Labs Announce Global License Agreement for Solid Tumor Imaging

03 12 2024 07:30:00 提供 Nasdaq GlobeNewswire

Lisata Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

12 11 2024 15:05:01 提供 Nasdaq GlobeNewswire

Lisata Therapeutics and Valo Therapeutics Announce Preclinical Research Collaboration

06 11 2024 08:23:21 提供 Nasdaq GlobeNewswire

Lisata Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update on Tuesday, November 12, 2024

06 11 2024 07:30:00 提供 Nasdaq GlobeNewswire

Lisata Therapeutics to Participate in Upcoming November 2024 Industry and Investor Events

31 10 2024 07:30:00 提供 Nasdaq GlobeNewswire

Lisata Therapeutics Announces Sponsored Preclinical Research Agreement with the University of Cincinnati to Study Certepetide for the Treatment of Endometriosis

28 10 2024 07:30:00 提供 Nasdaq GlobeNewswire

Lisata Therapeutics to Participate in Upcoming October 2024 Industry and Investor Events

03 10 2024 07:00:00 提供 Nasdaq GlobeNewswire

Lisata Therapeutics Announces First Patient Treated in the Second-line Cholangiocarcinoma Cohort of the BOLSTER Trial

17 9 2024 07:00:00 提供 Nasdaq GlobeNewswire

Lisata Therapeutics to Participate in Upcoming September 2024 Industry and Investor Events

09 9 2024 07:00:00 提供 Nasdaq GlobeNewswire

Lisata Therapeutics’ Certepetide Granted FDA Orphan Drug Designation for the Treatment of Cholangiocarcinoma

05 9 2024 07:00:00 提供 Nasdaq GlobeNewswire

Lisata Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

12 8 2024 15:05:00 提供 Nasdaq GlobeNewswire

Lisata Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update on Monday, August 12, 2024

05 8 2024 07:00:00 提供 Nasdaq GlobeNewswire

Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD™ Technology to Evaluate Efficacy of Pancreatic Cancer Therapy

18 7 2024 07:00:00 提供 Nasdaq GlobeNewswire

Lisata Therapeutics Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line Cholangiocarcinoma

16 7 2024 07:00:00 提供 Nasdaq GlobeNewswire

Lisata Therapeutics’ Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Cholangiocarcinoma in a Preclinical Model

10 7 2024 07:00:00 提供 Nasdaq GlobeNewswire

Lisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX Trial

13 6 2024 07:30:00 提供 Nasdaq GlobeNewswire